New hope for Hard-to-Treat blood cancers? early trial of CBX-250 begins
Disease control
Recruiting now
This early-phase trial is testing a new drug called CBX-250 in people with certain blood cancers (like acute myeloid leukemia) that have come back or not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 72 participants …
Phase: PHASE1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC